|
|
|
|
| LEADER |
01976nam a22003135i 4500 |
| 001 |
978-0-387-89520-8 |
| 005 |
20191021152622.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2009 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9780387895208
|
| 024 |
7 |
|
|a 10.1007/978-0-387-89520-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Therapeutic Targets of the TNF Superfamily
|c edited by Iqbal S. Grewal.
|
| 250 |
|
|
|a 1st ed. 2009.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2009.
|
| 300 |
|
|
|a XVII, 220 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in Experimental Medicine and Biology,
|v 647
|
| 505 |
0 |
|
|a Overview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets -- Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges -- Targeting TNF for Treatment of Cancer and Autoimmunity -- Targeting of BAFF and APRIL for Autoimmunity and Oncology -- The Role of FasL and Fas in Health and Disease -- OX40 (CD134) and OX40L -- Targeting CD70 for Human Therapeutic Use -- 4-1BB as a Therapeutic Target for Human Disease -- RANK(L) as a Key Target for Controlling Bone Loss -- Targeting the LIGHT-HVEM Pathway -- GITR: A Modulator of Immune Response and Inflammation -- Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases -- Tumor Necrosis Factor Receptor Superfamily Member 21: TNFR-Related Death Receptor-6, DR6 -- TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics -- Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
1 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Biomedicine, general.
|
| 700 |
1 |
|
|a Grewal, Iqbal S.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-0-387-89520-8
|